title: Nivolumab Doubles Survival for Patients with HNSCC.
abstract: In patients with head and neck squamous cell carcinoma refractory to platinum-based chemotherapy, those treated with nivolumab had a 30% reduction in the risk of death compared with those assigned to receive one of three single-agent chemotherapies, according to a recent phase III trial. In addition, 1-year survival among nivolumab recipients was double that of those who received a chemotherapeutic, the current standard of care.
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000821:virology; D017326:Clinical Trials, Phase III as Topic; D018572:Disease-Free Survival; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D000077594:Nivolumab; D030361:Papillomavirus Infections / Q000188:drug therapy / Q000453:epidemiology; D011379:Prognosis; D000077195:Squamous Cell Carcinoma of Head and Neck; D016019:Survival Analysis
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D000077594:Nivolumab